These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33058515)

  • 1. Neoadjuvant gemcitabine and nab-paclitaxel for borderline resectable pancreatic cancers: Intention-to-treat analysis compared with upfront surgery.
    Inoue Y; Saiura A; Oba A; Ono Y; Mise Y; Ito H; Sasaki T; Ozaka M; Sasahira N; Takahashi Y
    J Hepatobiliary Pancreat Sci; 2021 Feb; 28(2):143-155. PubMed ID: 33058515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer Potentially Improves Survival and Facilitates Surgery.
    Miyasaka Y; Ohtsuka T; Kimura R; Matsuda R; Mori Y; Nakata K; Kakihara D; Fujimori N; Ohno T; Oda Y; Nakamura M
    Ann Surg Oncol; 2019 May; 26(5):1528-1534. PubMed ID: 30868514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
    Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
    Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
    Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
    Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant
    Peterson SL; Husnain M; Pollack T; Pimentel A; Loaiza-Bonilla A; Westendorf-Overley C; Ratermann K; Anthony L; Desimone P; Goel G; Kudrimoti M; Dineen S; Tzeng CD; Hosein PJ
    Anticancer Res; 2018 Jul; 38(7):4035-4039. PubMed ID: 29970528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic cancer group.
    Seufferlein T; Uhl W; Kornmann M; Algül H; Friess H; König A; Ghadimi M; Gallmeier E; Bartsch DK; Lutz MP; Metzger R; Wille K; Gerdes B; Schimanski CC; Graupe F; Kunzmann V; Klein I; Geissler M; Staib L; Waldschmidt D; Bruns C; Wittel U; Fichtner-Feigl S; Daum S; Hinke A; Blome L; Tannapfel A; Kleger A; Berger AW; Kestler AMR; Schuhbaur JS; Perkhofer L; Tempero M; Reinacher-Schick AC; Ettrich TJ
    Ann Oncol; 2023 Jan; 34(1):91-100. PubMed ID: 36209981
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparative study of neoadjuvant treatment with gemcitabine plus nab-paclitaxel versus surgery first for pancreatic adenocarcinoma.
    Ielpo B; Caruso R; Duran H; Diaz E; Fabra I; Malavé L; Ferri V; Alvarez R; Cubillo A; Plaza C; Lazzaro S; Kalivaci D; Quijano Y; Vicente E
    Surg Oncol; 2017 Dec; 26(4):402-410. PubMed ID: 29113659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase II study of gemcitabine/nab-paclitaxel/S-1 combination neoadjuvant chemotherapy for patients with borderline resectable pancreatic cancer with arterial contact.
    Kondo N; Uemura K; Sudo T; Hashimoto Y; Sumiyoshi T; Okada K; Seo S; Otsuka H; Murakami Y; Takahashi S
    Eur J Cancer; 2021 Dec; 159():215-223. PubMed ID: 34781169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes of neoadjuvant gemcitabine, nab-paclitaxel, and S1 (GAS) in borderline resectable pancreatic cancer with arterial contact: Results from a phase II trial.
    Uemura K; Kondo N; Sudo T; Sumiyoshi T; Shintakuya R; Okada K; Baba K; Harada T; Murakami Y; Takahashi S
    J Hepatobiliary Pancreat Sci; 2024 May; 31(5):351-362. PubMed ID: 38156372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a Phase II Study on the Use of Neoadjuvant Chemotherapy (FOLFIRINOX or GEM/nab-PTX) for Borderline-resectable Pancreatic Cancer (NUPAT-01).
    Yamaguchi J; Yokoyama Y; Fujii T; Yamada S; Takami H; Kawashima H; Ohno E; Ishikawa T; Maeda O; Ogawa H; Kodera Y; Nagino M; Ebata T
    Ann Surg; 2022 Jun; 275(6):1043-1049. PubMed ID: 35258510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A Case of Pathological Complete Response Following Neoadjuvant Chemotherapy with Gemcitabine plus Nab-Paclitaxel in Borderline Resectable Pancreatic Cancer].
    Ohno N; Ishida M; Ohnishi K; Sawai K; Tabata S; Deguchi M; Kitajima T; Kaizaki Y
    Gan To Kagaku Ryoho; 2017 Nov; 44(12):1735-1738. PubMed ID: 29394759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Pancreatology; 2020 Sep; 20(6):1131-1138. PubMed ID: 32739267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients - Results of the RESPECT-Study.
    Weniger M; Moir J; Damm M; Maggino L; Kordes M; Rosendahl J; Ceyhan GO; Schorn S;
    Surg Oncol; 2020 Dec; 35():285-297. PubMed ID: 32949968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Prospective Study of Neoadjuvant Gemcitabine Plus Nab-paclitaxel in Patients with Borderline-resectable Pancreatic Cancer.
    Okano N; Matsuki R; Toki M; Gondo K; Ochiai K; Watanabe S; Tateishi H; Kogure M; Suzuki Y; Sugiyama M; Nagashima F; Shibahara J; Sakamoto Y; Furuse J
    Intern Med; 2023 Feb; 62(3):327-334. PubMed ID: 35793961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised phase 2 trial of nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in locally advanced or borderline resectable pancreatic adenocarcinoma.
    Reni M; Zanon S; Balzano G; Passoni P; Pircher C; Chiaravalli M; Fugazza C; Ceraulo D; Nicoletti R; Arcidiacono PG; Macchini M; Peretti U; Castoldi R; Doglioni C; Falconi M; Partelli S; Gianni L
    Eur J Cancer; 2018 Oct; 102():95-102. PubMed ID: 30149366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial).
    Okada KI; Shimokawa T; Hirono S; Kawai M; Sho M; Satoi S; Matsumoto I; Eguchi H; Murakami Y; Yamada S; Doi M; Yamaue H;
    Oncology; 2017; 93(5):343-346. PubMed ID: 28719890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized phase II study of gemcitabine and S-1 combination therapy versus gemcitabine and nanoparticle albumin-bound paclitaxel combination therapy as neoadjuvant chemotherapy for resectable/borderline resectable pancreatic ductal adenocarcinoma (PDAC-GS/GA-rP2, CSGO-HBP-015).
    Yamada D; Kobayashi S; Takahashi H; Akita H; Yamada T; Asaoka T; Shimizu J; Takeda Y; Yokoyama S; Tsujie M; Tomokuni A; Tanemura M; Morimoto O; Murakami M; Kim Y; Nakahira S; Hama N; Sugimoto K; Hashimoto K; Doki Y; Eguchi H
    Trials; 2021 Aug; 22(1):568. PubMed ID: 34446057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.